Literature DB >> 10757811

Hoxa9 immortalizes a granulocyte-macrophage colony-stimulating factor-dependent promyelocyte capable of biphenotypic differentiation to neutrophils or macrophages, independent of enforced meis expression.

K R Calvo1, D B Sykes, M Pasillas, M P Kamps.   

Abstract

The genes encoding Hoxa9 and Meis1 are transcriptionally coactivated in a subset of acute myeloid leukemia (AML) in mice. In marrow reconstitution experiments, coexpression of both genes produces rapid AML, while neither gene alone generates overt leukemia. Although Hoxa9 and Meis1 can bind DNA as heterodimers, both can also heterodimerize with Pbx proteins. Thus, while their coactivation may result from the necessity to bind promoters as heterodimers, it may also result from the necessity of altering independent biochemical pathways that cooperate to generate AML, either as monomers or as heterodimers with Pbx proteins. Here we demonstrate that constitutive expression of Hoxa9 in primary murine marrow immortalizes a late myelomonocytic progenitor, preventing it from executing terminal differentiation to granulocytes or monocytes in the presence of granulocyte-macrophage colony-stimulating factor (GM-CSF) or interleukin-3. This immortalized phenotype is achieved in the absence of endogenous or exogenous Meis gene expression. The Hoxa9-immortalized progenitor exhibited a promyelocytic transcriptional profile, expressing PU.1, AML1, c-Myb, C/EBP alpha, and C/EBP epsilon as well as their target genes, the receptors for GM-CSF, G-CSF, and M-CSF and the primary granule proteins myeloperoxidase and neutrophil elastase. G-CSF obviated the differentiation block of Hoxa9, inducing neutrophilic differentiation with accompanying expression of neutrophil gelatinase B and upregulation of gp91phox. M-CSF also obviated the differentiation block, inducing monocytic differentiation with accompanying expression of the macrophage acetyl-low-density lipoprotein scavenger receptor and F4/80 antigen. Versions of Hoxa9 lacking the ANWL Pbx interaction motif (PIM) also immortalized a promyelocytic progenitor with intrinsic biphenotypic differentiation potential. Therefore, Hoxa9 evokes a cytokine-selective block in differentiation by a mechanism that does not require Meis gene expression or interaction with Pbx through the PIM.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10757811      PMCID: PMC85621          DOI: 10.1128/MCB.20.9.3274-3285.2000

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  70 in total

1.  Meis proteins are major in vivo DNA binding partners for wild-type but not chimeric Pbx proteins.

Authors:  C P Chang; Y Jacobs; T Nakamura; N A Jenkins; N G Copeland; M L Cleary
Journal:  Mol Cell Biol       Date:  1997-10       Impact factor: 4.272

2.  The oncoprotein E2A-Pbx1a collaborates with Hoxa9 to acutely transform primary bone marrow cells.

Authors:  U Thorsteinsdottir; J Krosl; E Kroon; A Haman; T Hoang; G Sauvageau
Journal:  Mol Cell Biol       Date:  1999-09       Impact factor: 4.272

3.  The highest affinity DNA element bound by Pbx complexes in t(1;19) leukemic cells fails to mediate cooperative DNA-binding or cooperative transactivation by E2a-Pbx1 and class I Hox proteins - evidence for selective targetting of E2a-Pbx1 to a subset of Pbx-recognition elements.

Authors:  P S Knoepfler; M P Kamps
Journal:  Oncogene       Date:  1997-05-29       Impact factor: 9.867

Review 4.  Transcriptional regulation during myelopoiesis.

Authors:  N Lenny; J J Westendorf; S W Hiebert
Journal:  Mol Biol Rep       Date:  1997-08       Impact factor: 2.316

5.  C/EBPalpha bypasses granulocyte colony-stimulating factor signals to rapidly induce PU.1 gene expression, stimulate granulocytic differentiation, and limit proliferation in 32D cl3 myeloblasts.

Authors:  X Wang; E Scott; C L Sawyers; A D Friedman
Journal:  Blood       Date:  1999-07-15       Impact factor: 22.113

6.  PU.1 and the granulocyte- and macrophage colony-stimulating factor receptors play distinct roles in late-stage myeloid cell differentiation.

Authors:  K L Anderson; K A Smith; H Perkin; G Hermanson; C G Anderson; D J Jolly; R A Maki; B E Torbett
Journal:  Blood       Date:  1999-10-01       Impact factor: 22.113

7.  Mice bearing a targeted interruption of the homeobox gene HOXA9 have defects in myeloid, erythroid, and lymphoid hematopoiesis.

Authors:  H J Lawrence; C D Helgason; G Sauvageau; S Fong; D J Izon; R K Humphries; C Largman
Journal:  Blood       Date:  1997-03-15       Impact factor: 22.113

8.  Expression of HOX genes, HOX cofactors, and MLL in phenotypically and functionally defined subpopulations of leukemic and normal human hematopoietic cells.

Authors:  H Kawagoe; R K Humphries; A Blair; H J Sutherland; D E Hogge
Journal:  Leukemia       Date:  1999-05       Impact factor: 11.528

9.  Expression of the myeloperoxidase gene in acute and chronic myeloid leukemias: relationship to the expression of cell cycle-related genes.

Authors:  S Ferrari; E Tagliafico; G Ceccherelli; L Selleri; B Calabretta; A Donelli; P Temperani; M Sarti; S Sacchi; G Emilia
Journal:  Leukemia       Date:  1989-06       Impact factor: 11.528

10.  DNA rearrangement of a homeobox gene in myeloid leukaemic cells.

Authors:  C Blatt; D Aberdam; R Schwartz; L Sachs
Journal:  EMBO J       Date:  1988-12-20       Impact factor: 11.598

View more
  55 in total

1.  Differential and common leukemogenic potentials of multiple NUP98-Hox fusion proteins alone or with Meis1.

Authors:  Nicolas Pineault; Carolina Abramovich; Hideaki Ohta; R Keith Humphries
Journal:  Mol Cell Biol       Date:  2004-03       Impact factor: 4.272

2.  Quantitative expansion of ES cell-derived myeloid progenitors capable of differentiating into macrophages.

Authors:  Justin I Odegaard; Divya Vats; Lina Zhang; Roberto Ricardo-Gonzalez; Kristi L Smith; David B Sykes; Mark P Kamps; Ajay Chawla
Journal:  J Leukoc Biol       Date:  2006-12-08       Impact factor: 4.962

3.  C/EBPalpha binds and activates the PU.1 distal enhancer to induce monocyte lineage commitment.

Authors:  Christine Yeamans; Dehua Wang; Ido Paz-Priel; Bruce E Torbett; Daniel G Tenen; Alan D Friedman
Journal:  Blood       Date:  2007-08-01       Impact factor: 22.113

4.  Isolated Hoxa9 overexpression predisposes to the development of lymphoid but not myeloid leukemia.

Authors:  Sarah H Beachy; Masahiro Onozawa; Deborah Silverman; Yang Jo Chung; Mariela Martinez Rivera; Peter D Aplan
Journal:  Exp Hematol       Date:  2013-02-19       Impact factor: 3.084

5.  β-Catenin activates the HOXA10 and CDX4 genes in myeloid progenitor cells.

Authors:  Ling Bei; Chirag Shah; Hao Wang; Weiqi Huang; Rupali Roy; Elizabeth A Eklund
Journal:  J Biol Chem       Date:  2012-10-04       Impact factor: 5.157

6.  Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells.

Authors:  Polina Zjablovskaja; Petr Danek; Miroslava Kardosova; Meritxell Alberich-Jorda
Journal:  J Vis Exp       Date:  2018-02-21       Impact factor: 1.355

7.  Protein kinase C-mediated phosphorylation of the leukemia-associated HOXA9 protein impairs its DNA binding ability and induces myeloid differentiation.

Authors:  Ulka Vijapurkar; Neal Fischbach; Weifang Shen; Christian Brandts; David Stokoe; H Jeffrey Lawrence; Corey Largman
Journal:  Mol Cell Biol       Date:  2004-05       Impact factor: 4.272

8.  Conditional MN1-TEL knock-in mice develop acute myeloid leukemia in conjunction with overexpression of HOXA9.

Authors:  Hiroyuki Kawagoe; Gerard C Grosveld
Journal:  Blood       Date:  2005-08-16       Impact factor: 22.113

9.  Meis1 programs transcription of FLT3 and cancer stem cell character, using a mechanism that requires interaction with Pbx and a novel function of the Meis1 C-terminus.

Authors:  Gang G Wang; Martina P Pasillas; Mark P Kamps
Journal:  Blood       Date:  2005-03-08       Impact factor: 22.113

10.  Thrombopoietin induces HOXA9 nuclear transport in immature hematopoietic cells: potential mechanism by which the hormone favorably affects hematopoietic stem cells.

Authors:  Keita Kirito; Norma Fox; Kenneth Kaushansky
Journal:  Mol Cell Biol       Date:  2004-08       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.